Search Results - "Grosjean, Heidi"

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database by Grosjean, Heidi A I, Dolter, Samantha, Meyers, Daniel E, Ding, Philip Q, Stukalin, Igor, Goutam, Siddhartha, Kong, Shiying, Chu, Quincy, Heng, Daniel Y C, Bebb, D Gwyn, Morris, Don G, Cheung, Winson Y, Pabani, Aliyah

“…The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the…”
Get full text

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials by Gan, Chun L., Stukalin, Igor, Meyers, Daniel E., Dudani, Shaan, Grosjean, Heidi A.I., Dolter, Samantha, Ewanchuk, Benjamin W., Goutam, Siddhartha, Sander, Michael, Wells, Connor, Pabani, Aliyah, Cheng, Tina, Monzon, Jose, Morris, Don, Basappa, Naveen S., Pal, Sumanta K., Wood, Lori A., Donskov, Frede, Choueiri, Toni K., Heng, Daniel Y.C.

“…Immuno-oncology (IO)–based therapies have been approved based on randomised clinical trials, yet a significant proportion of real-world patients are not…”
Get full text

Platelet-Mediated NET Release Amplifies Coagulopathy and Drives Lung Pathology During Severe Influenza Infection by Kim, Seok-Joo, Carestia, Agostina, McDonald, Braedon, Zucoloto, Amanda Z, Grosjean, Heidi, Davis, Rachelle P, Turk, Madison, Naumenko, Victor, Antoniak, Silvio, Mackman, Nigel, Abdul-Cader, Mohamed Sarjoon, Abdul-Careem, Mohamed Faizal, Hollenberg, Morley D, Jenne, Craig N

“…The influenza A virus (IAV) causes a respiratory tract infection with approximately 10% of the population infected by the virus each year. Severe IAV infection…”
Get full text

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors by Meyers, Daniel E., Pasternak, Meghann, Dolter, Samantha, Grosjean, Heidi A.I., Lim, Chloe A., Stukalin, Igor, Goutam, Siddhartha, Navani, Vishal, Heng, Daniel Y.C., Cheung, Winson Y., Morris, Don G., Pabani, Aliyah

“…Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of…”
Get full text

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade by Navani, Vishal, Meyers, Daniel E., Ruan, Yibing, Boyne, Devon J., O'Sullivan, Dylan E., Dolter, Samantha, Grosjean, Heidi AI, Stukalin, Igor, Heng, Daniel Y.C., Morris, Don G., Brenner, Darren R., Sangha, Randeep, Cheung, Winson Y., Pabani, Aliyah

“…Immune checkpoint inhibitors (ICI) have revolutionized non-small cell lung cancer (NSCLC). We aimed to identify baseline characteristics, that are prognostic…”
Get full text

Acetylsalicylic acid inhibits intravascular coagulation during Staphylococcus aureus–induced sepsis in mice by Carestia, Agostina, Davis, Rachelle P., Grosjean, Heidi, Lau, Matthew W., Jenne, Craig N.

“…Antiplatelet therapies have been proposed for the treatment of sepsis, a syndrome resulting from a dysregulated immune response and inappropriate activation of…”
Get full text

Overview of reproductive and pregnancy health principles and practice used by maternal-fetal medicine specialists for fetal-neonatal neurology consultants by Soliman, Nancy, Kuret, Verena, Chan, Elaine, Smith, Christopher, Thomas, Mary-Anne, Mahallati, Houman, Grosjean, Heidi, Friebe, Erika, Rusnell, Leah

Get full text

Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced non-small cell lung cancer (LA-NSCLC): A population-based multicenter study by Lim, Chloe, Ghosh, Sunita, Morrison, Hali, Meyers, Daniel E., Stukalin, Igor, Dolter, Samantha, Grosjean, Heidi A.I., Kerba, Marc, Hao, Desiree, Pabani, Aliyah

“…8561 Background: The PACIFIC trial has drastically changed the LA-NSCLC treatment paradigm and improved survival outcomes with consolidation durvalumab…”
Get full text

Impact of performance status on survival outcomes and health care utilization in patients with advanced non–small cell lung cancer treated with immune checkpoint inhibitors by Meyers, Daniel E., Pasternak, Meghann, Dolter, Samantha, Grosjean, Heidi A.I., Lim, Chloe, Stukalin, Igor, Navani, Vishal, Heng, Daniel Yick Chin, Cheung, Winson Y., Morris, Don G., Pabani, Aliyah

“…9053 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm of non-small cell lung cancer (NSCLC). Despite the high…”
Get full text